<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

Anne Staylor

Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.

Recent Posts

4 min read

INS 2024: The Past, Present and Future of Neuromodulation

By Anne Staylor on 6/17/24 12:16 PM

INS President Dr. Marc Russo and INS President-Elect Dr. Konstantin Slavin discuss the current “state of the union” in neuromodulation, how the field is evolving and the challenges and opportunities that lie ahead in an interview with SmartTRAK at INS 2024.

At the 16th International Neuromodulation Society World Congress (INS 2024) held in Vancouver, Canada, Dr. Marc Russo, INS president, and Dr. Konstantin Slavin, INS president-elect, discussed the current “state of the union” in neuromodulation, how the field is evolving, where it’s going and trends in research, technology and clinical practice in an interview with SmartTRAK. They also discussed challenges and opportunities in the field, how the INS is addressing recent criticisms about neuromodulation and the promise and potential of neuromodulation across a wide range of clinical applications. 

To find out more, including the promising indications and areas of growth for spinal cord stimulation (SCS) and deep brain stimulation (DBS), click on the following video to listen to the interview recorded live at INS 2024 (51:53 min). Click hereto download a complete transcript of the interview. Topics by timecode are provided below. 

Continue Reading
3 min read

Inceptiv SCS: Offering Options in a Closed-Loop Device

By Anne Staylor on 4/26/24 11:56 AM

Medtronic’s David Carr, VP & GM, Pain Interventions, discusses Inceptiv closed-loop SCS in an interview with SmartTRAK.

Medtronic (MDT) announced FDA approval for the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS), the second closed-loop SCS device to reach the market using evoked compound action potentials (ECAPS). The company previously launched Inceptiv in Europe and Japan and plans to initiate Inceptiv’s US market launch in the coming weeks. 

SmartTRAK recently interviewed David Carr, MDT’s vice president and general manager of Pain Interventions, to learn more about Inceptiv, what differentiates it from other SCS devices and what it means for Medtronic and the SCS market. To listen to the interview, click on the following video (22:54 min). A link to download the complete transcript of the interview is also provided below. 


Anne Staylor here with BiomedGPS. Today, I am talking with David Carr, who is the vice president and general manager of Pain Interventions at Medtronic. Exciting news, David. Medtronic now has FDA approval for your Inceptiv SCS device, an ECAPs-based device. So David, tell me what does Inceptiv mean for Medtronic?

David Carr: Good afternoon, Anne, and thank you for your time today and your interest in this announcement for us. This is a big moment for Medtronic and especially for the pain team within Medtronic. This is technology that has taken many, many years to develop. If you think back to the pivotal RCT, we did ECHOMAC, which demonstrated the performance of closed-loop technology, the algorithm, many years ago. Six published manuscripts across many recognized journals. Twenty peer-reviewed abstracts and posters, data from over 200 patients and several million ECAPs. So this is not something that's just been developed in the last couple of years. There's been a tremendous amount of work invested in this platform. So this is a very big moment for Medtronic, finally getting approval with the FDA to launch the product in the US market. Because as you know, we've already launched this product in Europe and Japan, and we're already seeing the tremendous patient benefits that the product brings to the market.

Let's start by having you talk about the technology itself. What are the key differentiators for Inceptiv versus other ECAPs-based devices on the market?

DC: Well, there's only one other ECAP-based product on the market, and that product is essentially closed-loop paresthesia. Okay, what differentiates this product is ...

To download and read the complete interview "Inceptiv SCS: Offering Options in a Closed-Loop Device" with David Carr, VP and GM of Pain Interventions at Medtronic, just click the button below. Download the Transcript

Continue Reading
3 min read

Route 92 Medical: Raising the Bar in Neurovascular Thrombectomy

By Anne Staylor on 3/19/24 9:30 AM

Adam Hattan, VP of marketing for Route 92 Medical, discusses the SUMMIT MAX trial and provides an update on the company and products in an interview with SmartTRAK.

Route 92 Medical (R92) is raising the bar and advancing the treatment of acute ischemic stroke through its 250-patient SUMMIT MAX clinical trial, the first randomized controlled trial to evaluate the safety and effectiveness of “super-bore” 0.088” aspiration catheters. The company recently announced enrollment is complete in SUMMIT MAX, which features the company’s Monopoint Reperfusion System, including the HiPoint 88 and HiPoint 70 Reperfusion Catheters and the Tenzing Catheters. HiPoint is currently approved by the FDA as an access catheter, but the company plans to submit the results of SUMMIT MAX to the FDA to obtain the NRY indication, which would allow physicians to use the device on label as an aspiration catheter.

For an update on R92, its products and what SUMMIT​ MAX means for the company and market, SmartTRAK interviewed Adam Hattan, R92’s vice president of marketing. Click on the video below to listen to the interview, recorded via Google Meet (19:48 min). A link to download the complete transcript of the interview is also provided below.

Download the Adam Hattan Interview Transcript

Topics: Neurovascular
Continue Reading
3 min read

Medtronic: Making Waves At NANS 2024

By Anne Staylor on 2/6/24 9:40 AM

Medtronic executives discuss how the Company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024.

Medtronic’s David Carr, vice president and general manager of Pain Interventions, and Amaza Reitmeier, vice president and general manager of Brain Modulation, discuss the Company’s latest news, research and innovation in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 2024 Annual Meeting held January 18-21 in Las Vegas, Nevada.

To find out more, including the Company’s priorities and vision for interventional pain, minimally invasive spine and deep brain stimulation, click on the following video to listen to the interview (32:30 min). Topics by timecode are provided below, and you can click the button to download a transcript of the interview.

Download the Transcript

Interview Topics by Timecode:

00:27 David Carr introduction and background. Overview of Medtronic’s top news at NANS and the importance of the Company’s broad portfolio of pain intervention solutions, including stimulation, targeted drug delivery and interventional spine. 

04:28 Overview of Medtronic’s presence at NANS regarding clinical and scientific research vs competitors. Highlights of clinical data from Australian ECAPs study to support the introduction of the Inceptiv Spinal Cord Stimulation (SCS) system, what’s next for Inceptiv and how Inceptiv differs from other ECAP-based SCS devices. Discussion of other research and evidence to support expanded indications and health economics. Company strategies for leveraging data to drive adoption, reimbursement and growth in non-surgical refractory back pain and diabetic painful neuropathy (DPN),

Continue Reading
7 min read

What’s New in Neuromodulation? News to Know Before NANS 2024

By Anne Staylor on 1/9/24 9:30 AM

The North American Neuromodulation Society (NANS) is celebrating its 30th anniversary in 2024 and is once again bringing together the leading clinicians, researchers and manufacturers to Caesar’s Palace in Las Vegas for the NANS 2024 Annual Meeting, to be held January 18-21. To get you up to speed before the meeting, SmartTRAK has put together highlights of recent neuromodulation news. The following is just a small sampling of recent Neuromodulation-related news and updates from around the world compiled, reviewed and posted in real-time every day by the expert analysts at SmartTRAK.

SmartTRAK will be attending NANS 2024 from January 18-21. If you'd like to meet with us in person, please reach out to Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro Therapies, at anne.staylor@smarttrak.com, or just click the button below. Meet with SmartTRAK

Continue Reading
2 min read

BREAKING NEWS - Nevro Acquires VYRSA Technologies

By Anne Staylor on 12/1/23 1:49 PM

Nevro* (NVRO) announced it acquired VYRSA Technologies*, a privately held company focused on the minimally invasive treatment of chronic sacroiliac joint (SI Joint) pain. According to the Company, VYRSA is the only SI joint company that manufactures and supports a complete portfolio of FDA-cleared, state-of-the-art SI joint fusion devices. The acquisition was signed and closed on Nov 30, 2023. 

NVRO paid $40MM at closing and agreed to pay up to an additional $35MM in cash or stock tied to milestones. NVRO CEO Kevin Thornal said VYRSA offers differentiated implants to the Company’s current call point of physicians and will help drive company growth, adding that the technology will help bring long-term pain relief to the 15-30% of people suffering with chronic low back pain associated with the SI joint.

The US MIS SI Joint Fusion Market is the fastest-growing segment in the US Spine Market and a growing number of pain physicians are performing these procedures. According to SmartTRAK’s recently published 2023 US MIS SI Joint Market Report, this market is projected to grow at +18% CAGR over the next five years and 53+ MIS SI Joint Fusion systems are now commercially available in the US. See 2023 MIS SI Joint Fusion Market Report*.

The Company also announced the closing of a six-year, $200MM term loan credit facility to be used to repurchase the majority of its 2025 Convertible Notes and for working capital and other corporate purposes. NVRO CFO Rod MacLeod noted that the Company was pleased to refinance a majority of its debt and push the maturity out to 2029 while limiting equity dilution to 2.6MM warrant shares. 

Continue Reading
3 min read

Medtronic: Expanding Access to Neurovascular Interventions

By Anne Staylor on 10/17/23 9:30 AM

Medtronic Neurovascular President Dan Volz discusses expanding patient access to neurovascular therapies through innovation and globalization in an interview with SmartTRAK.

Medtronic Neurovascular President Dan Volz discusses innovation, globalization and the Company’s plans to double the number of neurovascular patients treated annually in three years in an interview with SmartTRAK. Volz said the Company is driving growth in Neurovascular through innovative business models and strategic investments in remote connectivity and the Medtronic Neurovascular Co-Lab Platform, a novel incubator designed to accelerate innovation in stroke care and treatment. To find out more about the Company and its latest innovations, click on the video to listen to the full interview (27:30 min). To download a transcript of the complete interview, just click the button below.

 

Anne Staylor here with SmartTRAK. Today I have the pleasure of interviewing Dan Volz, president of Medtronic Neurovascular. Dan, thank you for speaking with me today.

Dan Volz: It's my pleasure. It's good to talk to you.

I haven't talked to you for a while and I was hoping to catch up with you at SNIS when it was here in San Diego. Now that we are talking, let's just start broadly and talk from your perspective, what's important for us to know about Medtronic Neurovascular and what are your top priorities for fiscal year 2024?

DV: It's good to see you and I'm sorry that I missed you down in San Diego. That was a pretty quick up and back for me, but for us obviously it's about the patients and we had a pretty important milestone in 2022. In a 12-month period we helped treat 250,000 people, so that was a great celebration for us as a business. But I think even more importantly, it kicked off our strategic planning process to double that number in three years. And so everything that we do is centered on how do we drive toward that number? And there's a lot that goes into that, but it starts with obviously innovation and how are we innovating in our portfolio? What are we doing organically and what are we looking at inorganically to drive toward that number? And you know these statistics as well as anyone, there's 15 million strokes and we only treat five to 600,000 of them a year ...

To download and read the transcript of the complete interview with Dan Volz, president of Medtronic Neurovascular, by SmartTRAK's Anne Staylor, Executive Editor, VP & GM of Neuro Therapies, just clickthe button below. Download the Transcript

Continue Reading
3 min read

SNIS 2023: New Frontiers in Stroke Care: An Interview with J Mocco, MD

By Anne Staylor on 9/19/23 9:45 AM

SNIS President J Mocco, MD, discusses emerging technologies and new frontiers in neurointervention in an interview with SmartTRAK.

J Mocco, MD, President of the Society of Neurointerventional Surgery (SNIS), discusses the latest research and innovation in stroke care in an interview with SmartTRAK at the 20thAnnual Meeting of the SNIS recently held in San Diego, CA. To find out more regarding important research, emerging technologies and new frontiers in stroke care, listen to the following video. (27:12 min). A complete transcript of the interview can be downloaded below.


SmartTRAK: Hi, this is Anne Staylor with SmartTRAK. Today I'm covering the Society of Neurointerventional Surgery annual meeting here in San Diego, and I have the pleasure of speaking to J Mocco, MD, president of the SNIS. Dr. Mocco, thank you for talking with me today.

J Mocco, MD: Thank you very much for having me.

Well, this year I felt a lot of energy and vibrancy at the meeting, particularly when I walked into the exhibit hall, which is nice after some of the years we've had with COVID. One of the things I wanted to ask you is what are some of the exciting research studies at SNIS this year? Maybe you could just highlight some of the key research that is presented here at the meeting.

JM: 
Absolutely. I have to say this year was truly spectacular. The depth and breadth of new and exciting research and reports on technology and studies. This year we saw presentations on completely new technologies to treat brain aneurysms, multiple leap forwards in technologies to better remove clots from brains and cure people with stroke. Had very robust discussions on systems of care and how best to evaluate stroke patients. Is the current standard adequate? Should we have different methods of evaluating patient success? They're just examples of the really amazing things that are happening in this space in general, and particularly ...

To download the complete transcript of the interview with J Mocco, MD, President of SNIS, conducted by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies, just click the button below.Download the Transcript

Continue Reading
9 min read

What's New in the Neurovascular Market

By Anne Staylor on 8/1/23 9:53 AM

SmartTRAK constantly monitors the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. Contact Us if you'd like to learn how to receive these expert insights daily. Our users think it's the perfect way to start their day.

The following is just a small sampling of recent Neurovascular market updates from around the world compiled, reviewed and posted daily by our SmartTRAK analysts.

New Products:

  • ZOOM* - Imperative Care* 

    Imperative Care announced the completion of first cases using the recently FDA-cleared Zoom 88 Support catheter. One of the cases was an AIS patient with a tandem occlusion treated at Erlanger Health System in Chattanooga, TN. SmartTRAK reported FDA clearance of the device on Jun 15.

  •  MicroPort NeuroTech announced in May 2023 that it has completed the first clinical implantation of its NUMEN Detachable Embolization Coil for neurovascular aneurysm treatment in both the UK and Ireland.

  • EOSolutions Launches Dr. Banner BGC

     EOSolutions announced the full commercial launch of its Dr. Banner, Balloon Guide Catheter (BGC), developed in collaboration with InNeuroCo. According to the Company, the BGC features a 0.091 ID, proximal stability, distal trackability and a compliant polyurethane balloon.

Patents:

  • phenox*

    phenox GmbH’s US Patent Application “Insertion System For Implants For Treatment Of Bifurcation Aneurysms” was published disclosing a Y-shaped tubular implant and Y-shaped insertion catheter for bifurcation aneurysm treatment. 20230233347

  • Aspiration Catheter with an Adjustable Tip

    The Univ of Toledo’s US Patent Application “Aspiration Catheter With An Adjustable Tip For The Intracranial Circulation” was published disclosing a neurovascular aspiration catheter with an adjustable tip controlled by pull wires. 20230233221

    Learn More about Subscribing to SmartTRAK

Topics: Neurovascular
Continue Reading
2 min read

Fingers Crossed for a Market Recovery: Q123 Neuromodulation Market Recap

By Anne Staylor on 7/28/23 9:23 AM

Neuromodulation companies are keeping their fingers crossed that the positive growth in Q123 is a sign that market recovery is well underway.  

With three of the four top neuromodulation companies reporting high-single-digit (HSD) growth in Q123, manufacturers are keeping their fingers crossed that market recovery is well underway. The impact of COVID has lessened significantly and several manufacturers reported that near-term improvement in healthcare staffing levels and post-COVID demand helped drive strong underlying procedure volumes in Q123. Competitors are also seeing gains on new and differentiated product offerings and expanded indications.

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles